Key result
Mitral valve replacement significantly reduced pulmonary arterial systolic pressure from 101.2 mmHg to 48.1 mmHg (P<0.05) with a low perioperative mortality rate of 3.1%.
Why the study?
Does mitral valve replacement improve pulmonary arterial pressures and survival in patients with severe pulmonary arterial hypertension following mitral valve disease?
Population
32 patients with rheumatic mitral valve disease and severe pulmonary arterial hypertension, mean age 53.1…
Design
Cohort
Follow-up
mean 26.3 ± 10.7 months (range, 12–45 months)
Authors
Loading...
MVR associated with marked PASP reduction and low mortality in severe mitral PAH; leaves open survival effects and need for RCTs.
Cohort (n=32)
No
Does mitral valve replacement improve pulmonary arterial pressures and survival in patients with severe pulmonary arterial hypertension following mitral valve disease?
Absolute Event Rate: 48.1% vs 101.2%
p-value: p=<0.05
Mitral valve replacement in patients with severe pulmonary arterial hypertension due to mitral valve disease is associated with an acceptable perioperative risk and significant reductions in pulmonary pressures.
Song et al. (2015) conducted a cohort in Severe pulmonary arterial hypertension following mitral valve disease (n=32). Mitral valve replacement vs. Preoperative baseline was evaluated on Pulmonary arterial systolic pressure (PASP) in mmHg (p=<0.05). Mitral valve replacement significantly reduced pulmonary arterial systolic pressure from 101.2 mmHg to 48.1 mmHg (P<0.05) with a low perioperative mortality rate of 3.1%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: